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Prescription opioids, such as oxycodone, are highly effective analgesics for clinical pain
management, but approximately 25% of patients who are prescribed opioids misuse
them, and 5%–10% develop an opioid use disorder (OUD). Effective therapies for
the prevention and treatment of opioid abuse and addiction need to be developed.
The present study evaluated the effects of the highly selective dopamine D3
receptor antagonist VK4-116 ([R]-N-[4-(4-[3-chloro-5-ethyl-2-methoxyphenyl]piperazin-
1-yl)-3-hydroxybutyl]-1H-indole-2-carboxamide) on oxycodone addictive-like behaviors.
We used a model of extended access to oxycodone self-administration and tested the
effects of VK4-116 on the escalation of oxycodone self-administration and withdrawal-
induced hyperalgesia and irritability-like behavior in male and female rats. Pretreatment
with VK4-116 (5–25 mg/kg, i.p.) dose-dependently decreased the escalation of
oxycodone self-administration and reduced withdrawal-induced hyperalgesia and
irritability-like behavior in opioid-dependent rats. These findings demonstrate a key role
for D3 receptors in both the motivation to take opioids and negative emotional states that
are associated with opioid withdrawal and suggest that D3 receptor antagonism may be
a viable therapeutic approach for the treatment of OUD.
Keywords: VK4-116, escalation, opioid, dependance, withdrawal
INTRODUCTION
More than 2 million Americans currently suffer from substance use disorders that are related to
prescription opioid pain relievers, including oxycodone (Oxycontinr, Roxycodoner, Oxectar),
and 500,000 are addicted to heroin (Substance Abuse and Mental Health Services Administration,
2013). Over the past 20 years, the consumption of oxycodone increased by ∼500%, and
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opioid-related overdose deaths quadrupled (Kolodny et al., 2015;
Compton et al., 2016). Although opioid medications effectively
treat acute pain and help relieve chronic pain for some patients
(Moore et al., 2013), their use presents a dilemma for healthcare
providers because of the risk of addiction. Only three treatments
have been approved by the United States Food and Drug
Administration for the treatment of opioid use disorder (OUD):
methadone, buprenorphine, naltrexone, and their combination
(e.g., Suboxone) or extended-release formulations (e.g., Vivitrol).
Methadone is a synthetic opioid compound that binds primarily
to the µ-opioid receptor (MOR), and buprenorphine is a
MOR partial agonist. Methadone and buprenorphine are
particularly effective in reducing opioid-induced mortality and
maintaining patients in treatment, but important safety concerns
and strict regulations because of their agonist properties at
MORs have limited their use (National Academies of Sciences,
Engineering, and Medicine, 2018). Naltrexone has lower efficacy
and poor treatment adherence that have limited its real-world
effectiveness (Ndegwa et al., 2016). The recent introduction
of extended-release naltrexone (Vivitrol) has slightly improved
the use of naltrexone compared with previous formulations
(Ndegwa et al., 2016). New treatments for OUD with better
efficacy and without agonistic effects at the MOR need
to be developed.
Compelling evidence from animal studies suggests the
involvement of dopamine D3 receptors in the development of
addictive behaviors that are caused by many drugs of abuse,
including opioids (Heidbreder and Newman, 2010; Sokoloff
and Le Foll, 2017). D3 receptor antagonism has been shown
to attenuate nicotine (Ross et al., 2007), oxycodone (You
et al., 2019), and cocaine (Xi et al., 2005) self-administration,
conditioned place preference (CPP) that is induced by drugs
of abuse (Ashby et al., 2003; Song et al., 2013), and the
reinstatement of drug-seeking behavior that is triggered by drug
priming (Vorel et al., 2002; Andreoli et al., 2003; Xi and Gardner,
2007), stress (Xi and Gardner, 2007), and drug-associated cues
(Aujla and Beninger, 2005; Higley et al., 2011; Galaj et al.,
2015). Moreover, D3 receptor antagonism reduces locomotor
sensitization and reverses the lowering of brain stimulation
reward thresholds that is induced by drugs of abuse (Sonntag
et al., 1992; Pak et al., 2006; Spiller et al., 2008; Higley et al.,
2011). In contrast, D3 receptor antagonism does not affect the
seeking of natural rewards, such as sucrose self-administration
and sexual activity (Sonntag et al., 1992; Clément et al., 2009;
Higley et al., 2011; You et al., 2017). However, all of these
studies were conducted in animals that were subjected to
limited-access opioid self-administration (e.g., 3 h/day). The
efficacy of D3 receptor antagonism in animals that exhibit the
escalation of opioid intake and opioid dependance remains
to be determined. Therefore, the present study tested the
effects of the highly selective D3 receptor antagonist VK4-
116([R]-N-[4-(4-[3-chloro-5-ethyl-2-methoxyphenyl]piperazin-
1-yl)-3-hydroxybutyl]-1H-indole-2-carboxamide; in vitro
profile: D3 receptor Ki = 6.8 nM, 1,700-fold greater selectivity for
D3 receptors vs. D2 receptors, and metabolic stability in mouse
microsomes; Kumar et al., 2016; You et al., 2019) on oxycodone
self-administration and withdrawal-induced hyperalgesia and
irritability-like behavior in rats. The rats were given extended
access to oxycodone self-administration, a model with high
face validity, predictive validity, and construct validity for OUD
(Zhang et al., 2014; Wade et al., 2015). This model is highly
relevant to substance use disorders (Edwards and Koob, 2013;
George et al., 2014) and associated with neuroadaptations that
are also observed in humans with substance use disorders
(Adinoff et al., 1990; Briand et al., 2008; George et al., 2008, 2012;
Vendruscolo et al., 2012). The escalation model has been shown
to exhibit seven of the 11 criteria of the Diagnostic and Statistical
Manual of Mental Disorders, 5th edition (DSM-5; American
Psychiatric Association, 2013), including most of the criteria that
are required for severe use disorder: (1) tolerance (Ben-Shahar
et al., 2006); (2) withdrawal (Ahmed et al., 2002; Vendruscolo
et al., 2011); (3) substance taken in larger amount than intended
(Ahmed and Koob, 1998); (4) unsuccessful efforts to quit
(Ahmed and Cador, 2006; Lenoir et al., 2007); (5) considerable
time spent to obtain the drug (Wee et al., 2008); (6) important
social, work, or recreational activities given up because of use
(George et al., 2008; Lenoir et al., 2013); and (7) continued
use despite adverse consequences (Vanderschuren and Everitt,
2004; Vendruscolo et al., 2012; Xue et al., 2012; Seif et al., 2013).
The use of extended-access oxycodone self-administration
in animal strains that exhibit large individual differences,
such as heterogeneous stock (HS) rats (Hansen and Spuhler,
1984; Woods and Mott, 2017), may provide new insights
into the development of VK4-116 as a potential treatment
for OUD.
The effect of VK4-116 on oxycodone intake (i.e., the primary
endpoint in the present study to evaluate treatment efficacy)
was tested in two independent cohorts of rats using different
experimental designs (between-subjects and within-subjects) to
confirm reproducibility. The effects of VK4-116 on hyperalgesia
and irritability-like behavior that were associated with oxycodone
withdrawal were tested using a within-subjects design.
MATERIALS AND METHODS
Animals
Male and female HS rats were generated at the National Institutes
of Health in the 1980s to encompass as much genetic diversity as
possible by outbreeding eight inbred rat strains (ACI/N, BN/SsN,
BUF/N, F344/N, M520/N, MR/N, WKY/N, and WN/N; Hansen
and Spuhler, 1984). The HS rats (n = 60, n = 50 for the between-
subjects experiment, n = 10 for the within-subjects experiment)
were provided by Dr. Leah Solberg Woods (Medical College of
Wisconsin, now at Wake Forest University School of Medicine)
and housed two per cage on a reverse 12 h/12 h light/dark
cycle (lights off at 8:00 AM) in a temperature (20–22◦C) and
humidity (45%–55%) controlled vivarium with ad libitum access
to tap water and food pellets (PJ Noyes Company, Lancaster, NH,
USA). All of the procedures were conducted in strict adherence
to the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of The Scripps Research
Institute. At the time of testing, the rats’ body weights ranged
between 350 and 400 g.
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Intravenous Catheterization
The animals were anesthetized by isoflurane inhalation, and
intravenous catheters were aseptically inserted in the right
jugular vein using a modified version of a procedure that was
described previously (de Guglielmo et al., 2015, 2017). The vein
was punctured with a 22-gauge needle, and the tubing was
inserted and secured inside the vein by tying the vein with
suture thread. The catheter assembly consisted of an 18 cm
length of Micro-Renathane tubing (0.023-inch inner diameter,
0.037-inch outer diameter; Braintree Scientific, Braintree, MA,
USA) that was attached to a guide cannula (Plastics One,
Roanoke, VA, USA). The guide cannula was bent at a near
right angle, embedded in dental acrylic, and anchored with
mesh (2 cm square). The catheter exited through a small
incision on the back, and the base was sealed with a small
plastic cap and metal cover cap. This design helped to keep the
catheter base sterile and protected. The catheters were flushed
daily with heparinized saline (10 U/ml of heparin sodium;
American Pharmaceutical Partners, Schaumburg, IL, USA) in
0.9% bacteriostatic sodium chloride (Hospira, Lake Forest, IL,
USA) that contained 20 mg/0.2 ml of the antibiotic Timetin
(GlaxoSmithKline, Brentford, UK).
Operant Training
Self-administration was performed in operant conditioning
chambers (29 cm × 24 cm × 19.5 cm; Med Associates, St.
Albans, VT, USA) that were enclosed in sound-attenuating,
ventilated environmental cubicles. The front door and back wall
of the chambers were constructed of transparent plastic, and
the other walls were opaque metal. Each chamber was equipped
with two retractable levers that were located on the front panel.
Oxycodone was delivered through plastic catheter tubing that
was connected to an infusion pump. The infusion pump and
a cue light were activated by responses on the right (active)
lever. Responses on the left (inactive) lever were recorded but
did not have any scheduled consequences. Activation of the
pump resulted in the delivery of 0.1 ml of the fluid. A computer
controlled fluid delivery and behavioral data recording.
Oxycodone Self-administration
Each session was initiated by the extension of two retractable
levers into the operant chamber. Responses on the right active
lever were reinforced on a fixed-ratio 1 (FR1) schedule by
intravenous oxycodone (150 µg/0.1 ml/kg/infusion) that was
infused over 6 s, followed by a 20 s timeout period that
was signaled by the illumination of a cue light above the
active lever. Daily 12-h sessions were conducted for 15 days
(five sessions/week). Responses on the left inactive lever were
recorded but had no scheduled consequences. The animals had
access to food but not water during the 12-h session.
Drugs
Oxycodone (Sigma Aldrich, St. Louis, MO, USA) was dissolved
in 0.9% sodium chloride (Hospira, Lake Forest, IL, USA) and
administered at a dose of 150 µg/0.1 ml/kg. The dose of
oxycodone was selected based on previous studies (Wade et al.,
2015; Nguyen et al., 2019) and because it produces significant
plasma oxycodone concentrations (40 ng/ml; Mavrikaki et al.,
2017). VK4-116 was synthesized by Kumar et al. (2016) in the
Newman laboratory at the National Institute on Drug Abuse,
based on a published procedure. VK4-116 was dissolved in 25%
2-hydroxypropyl-β-cyclodextrin and intraperitoneally injected
at doses of 0, 5, 15, and 25 mg/kg as previously reported
(You et al., 2019).
Mechanical Nociceptive Von Frey Testing
Mechanical nociception, reflected by hind paw withdrawal
thresholds, was determined by an observer who was blind to
the experimental conditions using von Frey filaments, ranging
from 8.511 to 281.838 g. The test was performed similarly to
previous studies (Kallupi et al., 2018; Kononoff et al., 2018). The
test began after 10 min of habituation to the testing environment.
A series of von Frey filaments were applied from below the
wire mesh to the central region of the plantar surface of the
left hind paw in ascending order of force, beginning with the
smallest filament (8.511 g). The filament was applied until
buckling of the hair occurred, and the filament remained in
place for 2 s. Rapid withdrawal of the hind paw was considered
a positive response. The stimulus was incrementally increased
until a positive response was observed and then decreased until
a negative response was observed to determine a pattern of
responses to apply to previously described statistical methods
(Dixon, 1980). Once the threshold was determined for the left
hind paw, the same testing procedure was applied to the right
hind paw after 5 min. The 50% paw withdrawal threshold was
determined by the formula Xf + kδ, where Xf is the last von
Frey filament applied, k is the Dixon value that corresponded
to the response pattern, and δ is the mean difference between
stimuli. Paw withdrawal thresholds were determined for rats
before self-administration (baseline) and 12 h after the last
self-administration session (12-h withdrawal).
Irritability-Like Behavior
To test irritability-like behavior during oxycodone withdrawal,
we used the bottle-brush test, based on themethods of Lagerspetz
and Portin (1968) and Riittinen et al. (1986) and modified
slightly for rats (Kimbrough et al., 2017). Irritability-like behavior
was tested 12 h after the last self-administration session
(12-h withdrawal). Irritability-like behavior was examined by
measuring aggressive and defensive responses during the bottle-
brush test. Irritability-like behavior sessions were conducted in a
randomized order for each animal. Testing consisted of 10 trials
per rat in plastic cages (10.5 inches × 19 inches × 8 inches;
Ancare, Bellmore, NY, USA) with fresh bedding. During each
trial, the rat started at the back of the cage. A bottle brush
was rotated toward the animal’s whiskers (from the front of the
cage) by a treatment-naive experimenter. The brush was rotated
around the whiskers of the rat for approximately 1 s. The brush
was then rotated back to the front of the cage where it was
allowed to hang vertically for approximately 2 s, during which
behavioral responses were recorded. A 10-s intertrial interval was
used. Three observers who were blind to treatment scored the
behaviors in real-time. For each rat, separate sums of aggressive
and defensive responses across all trials were determined for each
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FIGURE 1 | (A) Escalation of oxycodone intake in heterogeneous stock (HS) rats. ∗∗p < 0.01, ∗∗∗p < 0.001, vs. day 1. (B) Escalation of oxycodone intake in male
(blue) and female (salmon) HS rats. ∗∗p < 0.01, ∗∗∗p < 0.001, vs. day 1.
observer. Aggressive and defensive response scores for each rat
were then calculated by averaging the observers’ sums. This was
then used to calculate a group mean and SEM. The following
were scored as aggressive responses: smelling the target, biting
the target (during the initial phase of rotating the brush forward
and back to the starting position), boxing the target, following the
target, exploring the target (using paws or mouth to manipulate
the brush without biting or boxing), mounting the target, and
delayed biting (during the 2 s that the brush hung at the starting
position). The following were scored as defensive responses:
escaping from the target, digging, burying, defecation, jumping,
climbing, vocalization, and grooming. Grooming and digging
were additionally recorded during the 10-s intertrial intervals.
Effect of VK4-116 on the Escalation of
Oxycodone Self-administration
(Between-Subjects)
Rats (n = 50, 25 males and 25 females) were trained to
self-administer oxycodone under an FR1 schedule of
reinforcement in daily 12-h sessions. Each active lever
press resulted in the delivery of one oxycodone infusion
(150µg/kg/0.1 ml infusion). A 20-s timeout period followed each
oxycodone infusion. During the timeout period, responses on the
active lever did not have scheduled consequences. This timeout
period occurred concurrently with the illumination of a cue light
that was located above the active lever to signal delivery of the
positive reinforcement. The rats were trained to self-administer
oxycodone in fourteen 12-h sessions (5 days/week). At this point,
the rats were divided into four groups (n = 12/13 group with
similar intake) and intraperitoneally injected with VK4-116 (0,
5, 15, and 25 mg/kg) 30 min before beginning the session.
Effect of VK4-116 on the Escalation of
Oxycodone Self-administration and
Withdrawal-Induced Hyperalgesia and
Irritability-Like Behavior (Within-Subjects)
A separate group of rats (n = 10, four males and six females)
were trained to self-administer oxycodone as described above.
After 14 sessions of oxycodone self-administration, the animals
were intraperitoneally injected with VK4-116 (0, 15, and
25 mg/kg) in a counterbalanced order to evaluate the effects
of VK4-116 on withdrawal-induced hyperalgesia using the von
Frey test. At the end of the hyperalgesia test, the animals
were allowed to self-administer oxycodone so that the effects
of VK4-116 on self-administration were assessed again using a
Latin-square design. The animals were subjected to oxycodone
self-administration at 2-day intervals between drug tests. At
the end of the Latin square, the rats were baselined again
for oxycodone self-administration and intraperitoneally injected
with VK4-116 (0 and 25 mg/kg) in a counterbalanced order
to evaluate the effects of VK4-116 on withdrawal-induced
irritability-like behavior.
Statistical Analysis
The self-administration data were analyzed using repeated-
measures analysis of variance (ANOVA) of the number of
infusions that were earned during the escalation interval. The
effects of VK4-116 on self-administration and hyperalgesia were
analyzed using appropriate one- or two-way ANOVAs (between-
or within-subjects) according to the experimental design. The
irritability-like behavior data were analyzed using Student’s
t-test. Significant effects in the ANOVA were followed by the
Newman–Keuls post hoc test. Values of p< 0.05 were considered
statistically significant.
RESULTS
Effect of VK4-116 on the Escalation of
Oxycodone Self-administration
Between-Subjects Study
After 3 weeks of oxycodone self-administration, the rats
gradually escalated their oxycodone intake (one-way ANOVA,
F(14,658) = 15.46, p < 0.001). The Newman–Keuls post
hoc test revealed the significant escalation of oxycodone
self-administration that began from session 6 until session
15 compared with the first day of extended access (p < 0.01 for
sessions 6–8; p < 0.001 for sessions 10–15; Figure 1A). The
two-way ANOVA that also incorporated sex as a variable
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indicated that both males and females escalated their oxycodone
intake, with a significant main effect of time (F(14,644) = 15.15,
p < 0.001). However, no differences in oxycodone intake
were observed between males and females, reflected by the
lack of a main effect of sex (F(1,46) = 2.738, p > 0.05)
and no sex × time interaction (F(1,46) = 0.614, p > 0.05;
Figure 1B). Treatment with VK4-116 significantly decreased
operant responding for oxycodone (F(3,44) = 3.454, p < 0.05).
The Newman–Keuls post hoc test revealed that VK4-116 reduced
oxycodone self-administration at the dose of 25 mg/kg (p< 0.05,
25 mg/kg vs. 0 mg/kg; Figure 2A). The two-way ANOVA
that also incorporated sex as a variable indicated that VK4-116
significantly reduced oxycodone intake in males and females,
reflected by a significant main effect of treatment (F(3,39) = 4.203,
p < 0.05), with no main effect of sex (F(1,39) = 0.703, p > 0.05)
and no sex × treatment interaction (F(3,39) = 0.004, p > 0.05;
Figures 2B,C). Inactive lever responding was low and unaltered
by VK4-116 treatment (Figures 2A–C, bottom panels).
Further analysis of the data allowed us to identify two different
subpopulations of rats. Using a median split, we were able to
divide the rats into High and Low responders based on their level
of oxycodone self-administration (unpaired t-test, t46 = 8.897,
p < 0.001; Figure 3A). The data on the effects of VK4-116
on oxycodone self-administration were then re-analyzed based
on the effects of VK4-116 on these two subpopulations, the
results of which showed that VK4-116 reduced oxycodone intake
selectively in High-responder rats. The two-way ANOVA, with
group (High and Low) and treatment (0, 5, 15, and 25 mg/kg)
as between-subjects factors, showed significant effects of group
(F(1,40) = 36.3, p< 0.001) and treatment (F(3,40) = 5.143, p< 0.01)
FIGURE 2 | (A) Effect of VK4116 on the escalation of oxycodone self-administration in HS rats. (B) Effect of VK4116 on the escalation of oxycodone
self-administration in male HS rats. (C) Effect of VK4116 on the escalation of oxycodone self-administration in female HS rats. The upper panels (a) represent
responses at the active lever. The lower panels (b) represent responses at the inactive lever. ∗p < 0.05, vs. 0 mg/kg; ###p < 0.001, vs. first day of oxycodone
self-administration.
FIGURE 3 | (A) Oxycodone self-administration in HS rats with high vs. low intake. ∗∗∗p < 0.001. (B) Effect of VK4116 in HS rats with high vs. low oxycodone intake.
∗p < 0.05, ∗∗p < 0.01, vs. 0 mg/kg.
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FIGURE 4 | (A) Schematic diagram of the experiment. (B) Escalation of oxycodone intake in HS rats. ∗p < 0.05, ∗∗p < 0.01, vs. day 1. (C) Effect of VK4116 in HS
rats (within-subjects design). The upper panel (a) represents responses at the active lever. The lower panel (b) represents responses at the inactive lever. ∗∗p < 0.01,
∗∗∗p < 0.001, vs. 0 mg/kg; ###p < 0.001, vs. first day of oxycodone self-administration. (D) Development of mechanical hyperalgesia after the escalation of
oxycodone self-administration in HS rats. ∗∗p < 0.01, vs. baseline (BSL). (E,F) Effect of VK4116 on oxycodone withdrawal-induced hyperalgesia. The data are
presented as grams of force applied. (E) ∗∗p < 0.01, vs. 0 mg/kg and as a percent change from baseline pre-oxycodone. (F) ∗∗p < 0.01, vs. BSL; ##p < 0.01, vs.
0 mg/kg.
FIGURE 5 | Effect of VK4116 on oxycodone withdrawal-induced irritability-like behavior. (A) Number of defensive responses. (B) Number of aggressive responses.
(C) Total irritability score (defensive + aggressive). ∗p < 0.05, ∗∗p < 0.01, vs. 0 mg/kg.
and a significant group × treatment interaction (F(3,40) = 3.441,
p < 0.05). The Newman–Keuls post hoc test revealed that
VK4-116 reduced oxycodone self-administration at doses of
15 mg/kg (p < 0.05) and 25 mg/kg (p < 0.01) selectively in
High-responder rats (Figure 3B).
Within-Subjects Study
After 3 weeks of oxycodone self-administration, the rats
gradually escalated their oxycodone intake (one-way ANOVA,
F(14,126) = 14.25, p < 0.0001). The Newman–Keuls post
hoc test revealed the significant escalation of oxycodone
self-administration that began from session 10 until session
15 compared with the first day of extended access (p < 0.05 for
session 10; p < 0.001 for sessions 11–15; Figures 4A,B).
The two-way ANOVA that also incorporated sex as a
variable indicated that both males and females escalated their
oxycodone intake, reflected by a significant main effect of time
(F(14,112) = 12.53, p< 0.001, data not shown), with no main effect
of sex (F(1,8) = 0.3883, p > 0.05) and no sex × time interaction
(F(14,112) = 0.3832, p > 0.05, data not shown). These results
confirmed the observations in the between-subjects experiment
that treatment with VK4-116 significantly decreased operant
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responding for oxycodone (F(2,18) = 13.68, p < 0.001). The
Newman–Keuls post hoc test revealed that VK4-116 reduced
oxycodone self-administration at both doses tested (p < 0.001,
25 mg/kg vs. 0 mg/kg; p < 0.0001, 25 mg/kg vs. 0 mg/kg;
Figure 4C). Inactive lever responding was low and unaltered by
VK4-116 treatment (Figure 4C, bottom panel).
Effect of VK4-116 on the Negative
Emotional State That Is Induced by
Oxycodone Withdrawal
At 12 h of withdrawal after 15 sessions of extended-
access oxycodone self-administration, the rats exhibited
the development of hyperalgesia, reflected by lower paw
withdrawal thresholds in the von Frey test compared with
baseline pre-oxycodone thresholds (t(9) = 4.825, p < 0.01;
Figure 4D). The one-way ANOVA indicated that treatment
with VK4-116 significantly reduced withdrawal-induced
hyperalgesia (F(2,18) = 7.017, p < 0.01). The Newman–Keuls
post hoc test revealed that VK4-116 reduced withdrawal-induced
hyperalgesia at the dose of 25 mg/kg (p < 0.01, 25 mg/kg vs.
0 mg/kg; Figure 4E). Figure 4F shows the data plotted as a
percentage of baseline before oxycodone exposure, indicating
that VK4-116 reduced withdrawal-induced hyperalgesia but not
to levels of the baseline response.
At the end of this experiment, the animals were baselined
again to determine their level of oxycodone self-administration
and tested for the effects of VK4-116 (25 mg/kg) on
irritability-like behavior 12 h into withdrawal. Treatment with
VK4-116 did not alter defensive responses (t(9) = 1.212, p< 0.01;
Figure 5A) but significantly reduced aggressive responses
(t(9) = 2.759, p < 0.01; Figure 5B) and the total irritability score
(t(9) = 3.484, p< 0.01; Figure 5C).
DISCUSSION
The present study used two different experimental designs
(between- and within-subjects) and found that D3 receptor
antagonism with VK4-116 dose-dependently reduced
oxycodone self-administration in oxycodone-dependent
male and female rats with a history of escalated oxycodone
self-administration. The reduction of oxycodone intake was
mainly driven by the effect of VK4-116 in a subpopulation
of rats that exhibited a high intake phenotype (i.e., High
responders). We then found that the effect of VK4-116 was
not limited to drug intake and also extended to a reduction of
withdrawal-induced hyperalgesia and irritability-like behavior in
oxycodone-dependent rats.
The effects of VK-116were similar inmale and female rats and
replicated using two different experimental designs (between-
andwithin-subjects). VK4-116 partially reversed the escalation of
oxycodone self-administration, which is consistent with previous
studies that reported that D3 receptor antagonism decreased
opioid self-administration in rats that were given limited access
to oxycodone or heroin self-administration (Boateng et al., 2015;
You et al., 2017; Jordan et al., 2019a) and decreased opioid-
induced CPP in rats (Ashby et al., 2003). The present results
replicated these findings and further demonstrated that VK4-116
was also effective in an animal model of opioid dependance.
The escalation of intake in opioid-dependent animals has
been hypothesized to be driven by the development of a negative
emotional state during opioid withdrawal (Koob, 2019). Opioid
withdrawal is characterized by hyperalgesia, irritability-like
behavior, and anxiety-like behavior (Edwards et al., 2012; Koob,
2019). We hypothesized that the effects that were observed in
self-administration studies might be mediated by the ability of
VK4-116 to alleviate the negative emotional state during opioid
withdrawal. As expected, pretreatment with VK4-116 attenuated
oxycodone withdrawal-induced hyperalgesia and irritability-like
behavior. These results are consistent with previous studies that
reported that VK4-116 dose-dependently attenuated naloxone-
precipitated conditioned place aversion in chronic oxycodone-
treated rats (You et al., 2019) and that the D3 receptor antagonist
SB-277011A blocked naloxone-precipitated conditioned place
aversion in chronic morphine-treated rats (Rice et al., 2012).
The inhibitory effects of VK4-116 on the escalation of
oxycodone self-administration and withdrawal-induced
hyperalgesia and irritability-like behavior are unlikely to be
attributable to nonspecific motor impairment because a previous
study that tested VK4-116 reported that it did not affect
locomotor activity (Kumar et al., 2016; Jordan et al., 2019b).
Moreover, treatment with VK4-116 and other D3 receptor
antagonists did not alter operant sucrose self-administration
(Vorel et al., 2002; Clément et al., 2009; Higley et al., 2011;
You et al., 2017).
In summary, the present study found that VK4-116 decreased
opioid self-administration and attenuated aversive states that
were induced by oxycodone withdrawal. The negative emotional
states that arise from drug withdrawal are considered to be
major factors that drive compulsive drug taking and seeking
in drug-dependent individuals (Koob and Mason, 2016; Koob
and Volkow, 2016). VK4-116 reduced the reinstatement of
drug-seeking behavior that was triggered by oxycodone priming
(Jordan et al., 2019a). Despite evidence of the involvement
of D3 receptors in drug addiction, the clinical translation of
these findings has been challenging because of insufficient
absorption, distribution, metabolism, and excretion properties
of D3 antagonists and possible cardiotoxicity when they are
administered in the presence of cocaine (Appel et al., 2015; Keck
et al., 2015). The only highly selective D3 receptor antagonist
that has been tested in humans is GSK598809, which was
evaluated for the treatment of obesity, nicotine dependence,
and alcohol dependence (Dodds et al., 2012; Mugnaini et al.,
2013; Murphy et al., 2017). Acute GSK598809 administration
produced a significant short-term reduction of nicotine craving
(Mugnaini et al., 2013), providing the first clinical evidence that
D3 receptor antagonism may be effective for the treatment of
substance use disorders.
VK4-116 has been shown to be highly selective and have
a stable metabolic profile across species (Kumar et al., 2016;
Jordan et al., 2019a). This metabolic stability distinguishes
VK4-116 from many previously characterized D3 receptor
ligands and suggests better translational potential (Jordan et al.,
2019a). Altogether, the present results and previous findings
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suggest that VK4-116 may be a promising pharmacotherapeutic
agent for the treatment of OUD given its ability to reduce
the motivation to take opioids and attenuate opioid
withdrawal symptoms.
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